Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Adma Biologics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ADMA alerts

About Adam Grossman

Adam Grossman is recorded as CFO at Adma Biologics, Inc. (ADMA) since April 1, 2024. Adma Biologics, Inc. reported in an 8-K filed February 28, 2024 that Adam Grossman was appointed Interim Chief Financial Officer, effective April 1, 2024. The proxy statement of Adma Biologics, Inc. reports total compensation of $10,237,326 for Adam Grossman in fiscal 2025, including a base salary of $925,000. Disclosed compensation is on record for 8 fiscal years. Adam Grossman has spoken on 26 earnings calls and 1 other investor event across 1 company, most recently for Adma Biologics, Inc. on August 5, 2026. Adma Biologics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Adma Biologics, Inc. includes Jerrold B (CEO and Board Member), Steven A. Elms (Chairman), Brad L. Tade (CFO) and 7 others.

“the Board has appointed Adam Grossman, President and Chief Executive Officer, as Interim Chief Financial Officer, effective as of April 1, 2024.”
Adma Biologics, Inc. Form 8-K, filed February 28, 2024 · Read the filing

Adam Grossman on recent calls

“Our second quarter results reflect strong execution across the business and demonstrate the power of Ascentive's long-term growth trajectory.”
CEO, Adma Biologics, Inc. Q2 FY2026 Earnings Call ·
“Let me take this opportunity to welcome all those present to this virtual annual meeting of stockholders of ADMA Biologics, Inc. We are excited to be hosting our virtual meeting, which allows us to be more inclusive and reach a greater number of stockholders.”
CEO, 2026 Annual Meeting of Stockholders ·
“We had a strong start to the year with earnings growth and margin expansion despite total revenue being essentially flat. underscoring the resilience of the business.”
CEO, Adma Biologics, Inc. Q1 FY2026 Earnings Call ·
“ADMA delivered a strong finish to 2025, reflecting disciplined execution across our commercial, manufacturing, and financial platforms. For the full year, total revenue was $510 million, representing 20% year-over-year growth.”
CEO, Adma Biologics, Inc. Q4 FY2025 Earnings Call ·
“ADMA delivered another record quarter of sequential and year-over-year growth, underscoring the strength of our business model and disciplined execution. We delivered total revenue of $134.2 million, representing a 10% quarter-over-quarter increase and 12% growth year-over-year.”
CEO, Adma Biologics, Inc. Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Adma Biologics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Adma Biologics, Inc. (ADMA) $925,000 $10,237,326
2024 Adma Biologics, Inc. (ADMA) $800,000 $7,918,734
2023 Adma Biologics, Inc. (ADMA) $750,000 $6,039,649
2022 Adma Biologics, Inc. (ADMA) $636,540 $2,649,501
2021 Adma Biologics, Inc. (ADMA) $618,000 $4,361,250
2020 Adma Biologics, Inc. (ADMA) $600,000 $1,962,141
2019 Adma Biologics, Inc. (ADMA) $536,000 $1,702,022
2018 Adma Biologics, Inc. (ADMA) $536,000 $1,553,300

Recent activity

Show 16 earlier activities